Tesamorelin: side effects, dangers and reviews
What are the side effects of tesamorelin? The most reliable data comes from clinical trials and the US product information leaflet for Egrifta. Here's what they report, the points to watch out for, and how much weight to give online reviews.
Tesamorelin 10 mg – €89.90The complete guide
The most frequent side effects
In phase 3 trials, the adverse events reported more frequently than with placebo were:
| Effect | What is reported |
|---|---|
| Injection site | Redness, itching, pain or irritation at the injection site |
| Joints | Joint pain (arthralgia) |
| Muscles and limbs | Muscle pain, pain in the arms or legs |
| Water retention | Swelling of the ankles or hands (peripheral edema) |
| Nerves | Tingling, numbness; carpal tunnel syndrome reported |
These effects, linked to the increase in growth hormone, were most often mild to moderate.
Blood sugar: the main point of concern
Like all growth hormone stimulants, tesamorelin can raise blood sugar and decrease insulin sensitivity. In the trials, blood glucose levels were monitored; the American leaflet indicates a risk of glucose intolerance, or even diabetes.
Other monitored effects
- IGF-1 : it increases, that's the desired effect; the leaflet advises monitoring it.
- Hypersensitivity reactions : skin rash, hives, rare.
- Antibody : antibodies against tesamorelin were detected in some of the participants, without any clear effect on its action.
Contraindications listed in the leaflet
The American package insert for Egrifta contraindicates tesamorelin in cases of pregnancy, hypothalamic-pituitary axis disorder (e.g., removal or irradiation of the pituitary gland), active cancer, or known allergy to the product.
Is tesamorelin dangerous?
The trials did not show any frequent serious side effects, but they were conducted within a specific framework: medically monitored participants over 26 to 52 weeks. Beyond that, long-term data are limited. In Europe, tesamorelin is not authorized for marketing; it is only available as a research peptide, intended for laboratory use. For a research vial, the primary risk is product quality: hence the importance of independent batch analysis.
How reliable are online reviews?
On forums, feedback mainly describes reactions at the injection site and water retention, which aligns with the trials. However, an opinion remains an isolated testimony: it says nothing about the dose, the purity of the product used, or what would have happened without it. To judge an effect, only studies with a placebo group are reliable.
Price
Tesamorelin 10 mg is €89.90 at MyPeptide, with its Janoshik report: 98.2% purity, 10.44 mg measured.
10 mg lyophilized vial (€8.99/mg), Janoshik analysis #244206: 98.2% purity, 10.44 mg measured. Shipped from the European Union in 2 to 5 business days; delivery €10, free from €160.
Tesamorelin 10 mg – €89.90Bacteriostatic water 3 ml – €5
- Tesamorelin: the complete guide
- Tesamorelin and visceral fat
- Tesamorelin and bodybuilding
- Retatrutide or tesamorelin
- Our Janoshik (COA) analysis
Frequently asked questions
What are the side effects of tesamorelin?
In clinical trials: reactions at the injection site, joint and muscle pain, water retention (edema), tingling. The main point of concern is the possible rise in blood glucose levels.
Does tesamorelin raise blood sugar levels?
It can raise blood sugar and decrease insulin sensitivity, like other growth hormone stimulants. The US product information leaflet indicates a risk of glucose intolerance.
Does tesamorelin cause water retention?
Yes, peripheral edema (swelling of the ankles or hands) is among the effects reported in the trials.
Is tesamorelin dangerous?
The trials did not show any frequent serious side effects in participants followed medically for 26 to 52 weeks. Long-term data are limited, and tesamorelin is not authorized in Europe.
What are the contraindications of tesamorelin?
According to the American leaflet: pregnancy, hypothalamic-pituitary axis disorder, active cancer and known allergy to the product.
Sources: FDA, Egrifta (tesamorelin) package insert; Falutz J. et al., N Engl J Med 2007; Falutz J. et al., J Clin Endocrinol Metab 2010. MyPeptide products are intended exclusively for scientific laboratory research.
